trial summary

No demonstrated result

suggested Heart failure by 20% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.94 [0.82 1.08]	p=1.00	0	4401	1	STOP-2 (ACEI vs felodipine or isradipine),
Cardiovascular death	1.06 [0.87 1.29]	p=1.00	0	4401	1	STOP-2 (ACEI vs felodipine or isradipine),
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	1.03 [0.85 1.26]	p=1.00	0	4401	1	STOP-2 (ACEI vs felodipine or isradipine),
Coronary event	0.87 [0.71 1.07]	p=1.00	0	4401	1	STOP-2 (ACEI vs felodipine or isradipine),
Fatal MI	no data
Heart failure	0.80 [0.64 1.00]	p=0.04	0	4401	1	STOP-2 (ACEI vs felodipine or isradipine),
Diabetes onset	no data
Peripheral arterial disease	no data
End stage renal disease	no data
All cause death	1.05 [0.89 1.22]	p=1.00	0	4401	1	STOP-2 (ACEI vs felodipine or isradipine),
non cardiovascular death	no data
Fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

suggested Heart failure by 37% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.94 [0.71 1.24]	p=1.00	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
Cardiovascular death	1.01 [0.72 1.42]	p=1.00	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
myocardial infarction (fatal and non fatal)	0.90 [0.74 1.09]	p=1.00	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
stroke (fatal and non fatal)	0.90 [0.74 1.09]	p=1.00	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
Coronary event	0.90 [0.74 1.09]	p=1.00	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
Fatal MI	no data
Heart failure	0.63 [0.52 0.77]	p=0.04	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
Diabetes onset	no data
Peripheral arterial disease	no data
End stage renal disease	no data
All cause death	1.02 [0.77 1.35]	p=1.00	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
non cardiovascular death	no data
Fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Fatal MI	no data
Heart failure	no data
Diabetes onset	no data
Peripheral arterial disease	no data
End stage renal disease	no data
All cause death	no data
non cardiovascular death	no data
Fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

suggested Heart failure by 20% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.94 [0.82 1.08]	p=1.00	0	4401	1	STOP-2 (ACEI vs felodipine or isradipine),
Cardiovascular death	1.06 [0.87 1.29]	p=1.00	0	4401	1	STOP-2 (ACEI vs felodipine or isradipine),
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	1.03 [0.85 1.26]	p=1.00	0	4401	1	STOP-2 (ACEI vs felodipine or isradipine),
Coronary event	0.87 [0.71 1.07]	p=1.00	0	4401	1	STOP-2 (ACEI vs felodipine or isradipine),
Fatal MI	no data
Heart failure	0.80 [0.64 1.00]	p=0.04	0	4401	1	STOP-2 (ACEI vs felodipine or isradipine),
Diabetes onset	no data
Peripheral arterial disease	no data
End stage renal disease	no data
All cause death	1.05 [0.89 1.22]	p=1.00	0	4401	1	STOP-2 (ACEI vs felodipine or isradipine),
non cardiovascular death	no data
Fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

suggested Heart failure by 37% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.94 [0.71 1.24]	p=1.00	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
Cardiovascular death	1.01 [0.72 1.42]	p=1.00	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
myocardial infarction (fatal and non fatal)	0.90 [0.74 1.09]	p=1.00	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
stroke (fatal and non fatal)	0.90 [0.74 1.09]	p=1.00	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
Coronary event	0.90 [0.74 1.09]	p=1.00	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
Fatal MI	no data
Heart failure	0.63 [0.52 0.77]	p=0.04	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
Diabetes onset	no data
Peripheral arterial disease	no data
End stage renal disease	no data
All cause death	1.02 [0.77 1.35]	p=1.00	0	4418	1	STOP 2 (ACEI vs diurectic or beta-blocker),
non cardiovascular death	no data
Fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with additional risk factor: 1 trials - JMIC-B

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Fatal MI	no data
Heart failure	no data
Diabetes onset	no data
Peripheral arterial disease	no data
End stage renal disease	no data
All cause death	no data
non cardiovascular death	no data
Fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with cardiovascular disease: 1 trials - JMIC-B

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Fatal MI	no data
Heart failure	no data
Diabetes onset	no data
Peripheral arterial disease	no data
End stage renal disease	no data
All cause death	no data
non cardiovascular death	no data
Fatal stroke	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients